Citius Pharmaceuticals Inc vs Endeavour Silver Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.69 (market cap $20.01M), while Endeavour Silver Corp trades at $10.66 (market cap $3.14B). The key difference: Endeavour Silver Corp is far larger — about 156.9× Citius Pharmaceuticals Inc's market cap, and Endeavour Silver Corp is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | EXK | |
|---|---|---|
Market Cap | $20.01M | $3.14B |
Sector | Health | Basic Materials |
52-Week High | $1.82 | $14.12 |
52-Week Low | $0.48 | $5.31 |
Enterprise Value | $16.23M | $3.14B |
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.
The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.
Endeavour Silver (EXK) trades at $10.68, up 4.3% today, with a bullish technical outlook driven by moving averages and strong analyst sentiment. The company reported Q2 2026 earnings in line with estimates at $0.15 per share, with revenue growth and operational execution highlighted in recent news. Financials show improving trends, with 2026 revenue projected at $737 million and net income turning positive to $66 million, though 2025 saw a net loss of $119 million. A new $25 million credit facility was secured in August 2026, supporting liquidity.
The stock offers upside to the consensus price target of $15.50, with 79% of analysts rating it Buy. Key risks include volatile silver prices, execution challenges at new mines, and high valuation multiples like a P/E of 52.95. Positive catalysts include production ramp-ups and favorable metal price outlooks, but investors should monitor debt levels and commodity cycles.
Trailing returns across standard periods
Latest headlines on both assets
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →